Kardatuxan

Rivaroxaban, the active ingredient in Kardatuxan, is a Direct Factor Xa inhibitor presented as an oral tablet for oral use. It is used to prevent stroke and systemic embolism in patients with non‑valvular atrial fibrillation and to treat or prevent venous thromboembolism. GNH USA supplies Kardatuxan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Rivaroxaban is a direct Factor Xa inhibitor used in several thromboembolic conditions.

- Non‑valvular atrial fibrillation: reduces the risk of stroke and systemic embolism. - Deep vein thrombosis and pulmonary embolism: treats acute events and prevents recurrence. - Orthopedic surgery (post‑operative): provides prophylaxis against venous thromboembolism.

Rivaroxaban may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Minor bleeding (e.g., nosebleeds, gum bleeding). - Bruising or hematoma formation. - Gastrointestinal discomfort such as nausea or dyspepsia. - Headache or dizziness. - Fatigue.

Serious or Rare Side Effects: - Intracranial hemorrhage. - Major gastrointestinal bleeding. - Spinal or epidural hematoma, especially after neuraxial procedures. - Severe allergic reactions including anaphylaxis. - Hepatic injury indicated by elevated liver enzymes. - Thrombocytopenia.

Before initiating therapy, consider the following safety measures.

- Renal impairment: assess kidney function; avoid or adjust use in severe impairment. - Hepatic disease: contraindicated in patients with severe hepatic disease. - Concomitant antiplatelet therapy: increased bleeding risk; monitor closely. - Surgical or invasive procedures: discontinue prior to the procedure as advised. - Pregnancy and breastfeeding: safety not established; avoid unless benefits outweigh risks. - Store at ambient temperature: keep below 25°C, protect from moisture and light.

Rivaroxaban interacts with several drug classes that can alter its anticoagulant effect.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir): increase exposure and bleeding risk. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): reduce efficacy and increase thrombosis risk. - Other anticoagulants (e.g., warfarin, heparin): additive bleeding risk.

Moderate Interactions (Monitor Closely): - Antiplatelet agents (e.g., aspirin, clopidogrel): heightened bleeding tendency. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may exacerbate gastrointestinal bleeding. - Selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline): potential increase in bleeding events.